Caplin Point Laboratories: September ’21 Results Update
Moneylife Digital Team 11 November 2021
Where other pharmaceuticals companies witnessed cost pressure due to rising raw materials prices, Caplin Point Laboratories (Caplin) reported a healthy quarter due to its differentiated model. To know more about its differentiated model, click here. Caplin’s revenues grew by 13% y-o-y (year-on-year) to Rs304 crore, driven by a strong growth across US and Latin America (LatAm) regions. LatAm...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
Already a subscriber ? Log in
Free Helpline
Legal Credit